At Spero Therapeutics, it is our hope to advance novel treatments for rare diseases and MDR bacterial infections.
Since our inception in 2013, we have been steadfast in our commitment to pioneering superior approaches for bacterial infections. Our founding was a response to the urgent need to combat severe infections and the escalating global crisis of antibiotic resistance. Our pipeline targets areas where approved therapies are scarce, or where the prevailing standards of care are suboptimal.